Celltrion said Friday that the company’s biosimilar products for autoimmune diseases -- Yuflyma and Remsima -- are set for further expansion in key European markets following the multiple bids it has secured there.

Celltrion said that Yuflyma, a copycat version to AbbVie’s Humira, won state bids for adalimumab in Friuli-Venezia Giulia and Sicily, Italy, last year. Celltrion will supply Yuflyma for four and a half years in FVG and for two years in Sicily.

Including the recent deals, Yuflyma won a total of 12 state tenders in Italy alone last year, the company added.

Yuflyma also continues to win bids in the Netherlands, home to the European Medicines Agency. Celltrion said that the company recently won a deal in the adalimumab bid held by Inkoopcombinatie Zuid Oost Nederland (ICZON), the regional drug purchasing organization for the southeastern Netherlands. The company added that Yuflyma will be provided to this region for the next three years.

"Yuflyma's high-concentration formulation is widely recognized for its product competitiveness, particularly for its ability to customize treatment to the patient's situation through dose diversity,” said Yoo Won-sik, the head of Celltrion’s office in Italy.

Celltrion is also expanding prescriptions of Remicade biosimilar Remsima's subcutaneous formulation version in Europe. In 2023, Celltrion won a total of six provincial tenders for the product in Italy, including a recent bid in the Sicilian region.

Celltrion’s Remsima also won a bid from the Inkoopcombinatie Ziekenhuis Apotheken Academische Ziekenhuizen, the largest group of university hospitals in the Netherlands and a key supply channel in the country.

In the Netherlands, Celltrion’s Remsima already held a 54 percent share in the country’s infliximab market, and the latest win will help the company to cement its presence in the country, the company added.

“Integrated Celltrion will allow the company to introduce a better pricing strategy and help the company continue its positive performance this year,” Yoo noted.